HIV Shot Lenacapavir Facing Access Barriers in Latin America
- Published:
- First detected:
Insights by Echo AI
Gilead Sciences' lenacapavir, a twice-yearly HIV prevention shot showing near 100% efficacy, faces access barriers in Latin American countries despite running crucial trials. Some countries face high prices, with activists protesting and officials criticizing Gilead's pricing. Brazil, Mexico, Argentina, and Peru are among those struggling to afford the drug, priced at $14,000 per dose in the US, with generic versions available for $40 in low- and middle-income countries.
Source coverage
4
records merged
0
0 unique
2
2 unique
2
1 unique
4 Sources
The HIV shot that could change medicine is facing its biggest test: Ge...
The HIV shot that could change medicine is facing its biggest test: Ge...
«Разгорается борьба за доступ к новому «чудодейственному» препарату от...
Unlock Echo Intelligence
Move beyond the public feed. Monitor breaking stories across Telegram, X, and the web — with earlier visibility, clearer context, and complete control over your sources.
- Monitor Telegram, X, and web in one place
- Add any source, from niche channels to global outlets
- Build custom feeds around events, regions, entities, or keywords
- Merge duplicate coverage into one clear, source-transparent story
- Auto-translate summaries and full articles
- Search past coverage and use AI-powered editorial tools
